Metoprolol-lnduced Hepatitis: Rechallenge and Drug Oxidation Phenotyping

Abstract

Brief Reports1 January 1988Metoprolol-lnduced Hepatitis: Rechallenge and Drug Oxidation PhenotypingDOMINIQUE LARREY, M.D., JEAN HENRION, M.D., FRANCIS HELLER, M.D., GERARD BABANY, M.D., CLAUDE DEGOTT, M.D., DOMINIQUE PESSAYRE, M.D., JEAN-PIERRE BENHAMOU, M.D.DOMINIQUE LARREY, M.D., JEAN HENRION, M.D., FRANCIS HELLER, M.D., GERARD BABANY, M.D., CLAUDE DEGOTT, M.D., DOMINIQUE PESSAYRE, M.D., JEAN-PIERRE BENHAMOU, M.D.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-108-1-67 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptMetoprolol is a widely used beta-adrenoreceptor antagonist. To our knowledge, there is no report of hepatitis involving this drug as well as other beta-adrenoreceptor antagonists (1). Metoprolol is metabolized by three major oxidation pathways (2); two of them, O-dealkylation and alpha-hydroxylation, undergo genetically controlled polymorphisms correlated with that of debrisoquine oxidation (2-4). This finding strongly suggests that metoprolol oxidation depends at least partly on the same isozyme of cytochrome P-450 involved in the genetic polymorphism of oxidation of debrisoquine and many other drugs such as sparteine, perhexiline, and several other beta-adrenoreceptor antagonists (5). Poor metabolizers of debrisoquine and metoprolol exhibit...References1. STRICKER B and SPOELSTRA P. Drug-Induced Hepatic Injury: A Comprehensive Survey of the Literature on Adverse Drug Reactions up to January 1985. Amsterdam: Elsevier; 1985: 96-7. Google Scholar2. SILAS J, MCGOURTY J, LENNARD M, TUCKER G, and WOODS H. Polymorphic metabolism of metoprolol: clinical studies. Eur J Clin Pharmacol. 1985;28 (suppl):85-8. CrossrefMedlineGoogle Scholar3. LENNARD M, SILAS J, FREESTONE S, RAMSAY L, TUCKER G, and WOODS H. Oxidation phenotype—a major determinant of metoprolol metabolism and response. N Engl J Med. 1982;307:1558-60. CrossrefMedlineGoogle Scholar4. MCGOURTY J, SILAS J, LENNARD M, TUCKER G, and WOODS H. Metoprolol metabolism and debrisoquine oxidation polymorphism—population and family studies. Br J Clin Pharmacol. 1985;20:555-66. CrossrefMedlineGoogle Scholar5. JACQZ E, HALL S, and BRANCH R. Genetically determined polymorphisms in drug oxidation. Hepatology. 1986;6:1020-32. CrossrefMedlineGoogle Scholar6. MORGAN M, RESHEF R, SHAH R, OATES N, SMITH R, and SHERLOCK S. Impaired oxidation of debrisoquine in patients with perhexiline liver injury. Gut. 1984;25:1057-64. CrossrefMedlineGoogle Scholar7. EVANS D, MAHGOUB A, SLOAN T, IDLE J, and SMITH R. A family and population study of the genetic polymorphism of debrisoquine oxidation in a white British population. J Med Genet. 1980;17:102-5. CrossrefMedlineGoogle Scholar8. SHEAR N, SPIELBERG S, GRANT D, TANG B, and KALOW W. Differences in metabolism of sulfonamides predisposing to idiosyncratic toxicity. Ann Intern Med. 1986;105:179-84. LinkGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAuthors: DOMINIQUE LARREY, M.D.; JEAN HENRION, M.D.; FRANCIS HELLER, M.D.; GERARD BABANY, M.D.; CLAUDE DEGOTT, M.D.; DOMINIQUE PESSAYRE, M.D.; JEAN-PIERRE BENHAMOU, M.D.Affiliations: Hôpital Beaujon Clichy France Hôpital de Jolimont Haine Saint-Paul Belgium PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byAcute liver injury induced by drug interaction between dacomitinib and metoprolol due to the inhibition of CYP2D6 by dacomitinibIdentification of Metoprolol Tartrate-Derived Reactive Metabolites Possibly Correlated with Its Cytotoxicityβ-Blocker-Induced Liver Injury: A Class Effect With Incidental RechallengeDrug-Induced Liver InjuryDrug-Induced Liver InjuryLevetiracetam-induced transaminitis in a young male with traumatic brain injuryDrug-induced HepatotoxicityMetoprololHepatotoxicity of Cardiovascular and Antidiabetic DrugsDrug-Induced Liver InjuryDrug‐Induced Liver DiseaseDrug-Induced Liver InjuryLiver Disease Caused by DrugsFatal subacute liver failure after repeated administration of sevoflurane anaesthesiaCiprofloxacin-Induced Hepatotoxicity Resolved with Levofloxacin: A Case Report and a Review of the LiteratureAtenolol Hepatotoxicity: Report of a Complicated CaseClopidogrel-Induced Hepatocellular Injury and Cholestatic Jaundice in an Elderly Patient: Case Report and Review of the LiteratureDrugs Used to Treat Hypertension, Heart Failure, and Angina PectorisMetoprololDrug-Induced Liver InjuryMetoprolol 37350-58-6Fosinopril-induced prolonged cholestatic jaundice and pruritus: first case reportAcute Cholestatic Hepatitis Associated With PravastatinGENETIC PREDISPOSITION TO DRUG-INDUCED LIVER DISEASEHepatotoxityHypersensitivity Immune Reaction as a Mechanism for Dilevalol-Associated HepatitisClinical consequences of polymorphic drug oxidationLabetalol HepatotoxicityJohn A. Clark, MD, MSPH, Hyman J. Zimmerman, MD, Lelia Ann Tanner, RPhFatal labetalol-induced hepatic injuryDrug-induced Liver DiseaseGenetically determined oxidation polymorphism and drug hepatotoxicityβ-Adrenoceptor antagonists and antianginal drugs 1 January 1988Volume 108, Issue 1Page: 67-68KeywordsDrugsGenetic polymorphismHepatitis AHepatitis B ePublished: 1 December 2008 Issue Published: 1 January 1988 PDF downloadLoading ...